IperionX Announces Issuance of 106,093 Shares Following Exercise of Unlisted Options

Details on IperionX’s Section 708A Notice and the 106,093 Share Issuance

On 15 July 2026, IperionX Limited submitted a formal notice to the Australian Securities Exchange under paragraph 708A(5)(e) of the Corporations Act 2001 (Cth), confirming the issuance of 106,093 fully paid ordinary shares due to the exercise of unlisted options. This Section 708A notice permits the company to issue shares without a prospectus, provided statutory conditions are met. The new shares belong to an existing quoted class on the ASX, making them freely tradable alongside existing ordinary shares.

The notice legally documents that the company met all requirements to issue shares without triggering disclosure obligations under Part 6D.2. For shareholders, this means the company’s capital structure now includes an additional 106,093 shares. Although the exercise price and total proceeds were not disclosed, the issuance is publicly recorded. Investors should incorporate this increase when analyzing potential dilution.

Compliance Statements Under the Corporations Act 2001

The Section 708A(5)(e) notice requires IperionX to declare statutory compliance for the issuance to be valid and for shares to trade freely. The company confirmed the shares were issued without disclosure under Part 6D.2. It also affirmed compliance with Chapter 2M, covering financial reporting and directors’ reports, as of the notice date.

Additionally, IperionX declared adherence to sections 674 and 674A, which govern continuous disclosure obligations for listed entities. Section 674 mandates immediate market disclosure of material information affecting share value, while section 674A covers further disclosure requirements. The company also confirmed no "excluded information" exists under sections 708A(7) and 708A(8). These declarations ensure the legality of the issuance and unrestricted trading of the new shares.

Overview of IperionX’s Dual-Listed Operations in Critical Minerals and Titanium

IperionX Limited trades on both the ASX and NASDAQ under the ticker IPX. Its US operations span Virginia, Tennessee, and Utah, including locations in South Boston, Camden, and West Valley City. This geographic spread supports the company’s strategy to develop a domestic US supply chain for titanium and critical minerals, an advanced materials sector gaining significant policy and investor focus.

Registered in Australia (ABN 84 618 935 372), IperionX directs investor and media inquiries through Australian contacts, reflecting its dual-jurisdiction structure. The company produces titanium metal via a lower-carbon, sustainable process aimed at supplying defence, aerospace, consumer electronics, and advanced manufacturing sectors. Its US sites, especially in Virginia and Utah, are strategically important due to their proximity to aerospace and defence manufacturing hubs. Consequently, IperionX’s capital structure, including options and share issuances, is closely monitored by investors in critical minerals and advanced materials.

Understanding Unlisted Options and Their Role in Share Issuances

Unlisted options grant holders the right to purchase company shares at a set price before a specified date but are not traded on the ASX. Typically issued to employees, directors, or consultants as incentives or through financing arrangements, exercising these options involves paying the exercise price to receive newly issued shares. Companies then lodge notices like this to ensure shares are freely tradable.

For the 15 July 2026 issuance, IperionX confirmed 106,093 fully paid ordinary shares were issued following option exercises. The company did not disclose the exercise price, option holders’ identities, or total cash received. These shares belong to an existing quoted class on the ASX, carrying identical rights and tradability. Exercising unlisted options is a common corporate event, with Section 708A providing a streamlined legal process for such issuances.

Effect of the Share Issuance on IperionX’s Capital Structure

The 106,093 share issuance adds incrementally to IperionX’s total shares outstanding. The company did not provide total shares on issue before or after this transaction, so investors should reference recent Appendix 3B filings or capital disclosures to assess dilution impact. Option exercises typically cause dilution, especially in growth-stage resource and advanced materials companies using equity incentives.

Investors should consider cumulative effects of option exercises on share count, as increased shares dilute earnings, assets, and value per share. The company did not disclose remaining options, exercise prices, or expiry dates in this update. For a full view of outstanding dilutive instruments, investors should consult IperionX’s latest annual report, meeting notices, or prior Appendix 3Bs.

Significance of IperionX’s US Operations for the Titanium Supply Chain

IperionX’s operations in Virginia, Tennessee, and Utah form part of its strategy to build a vertically integrated, US-based titanium supply chain. The Virginia site hosts the Titan Project, a key mineral resource asset, while Tennessee and Utah support processing and materials activities. This geographic diversity aligns with US government priorities to secure domestic critical minerals and advanced materials sources.

Titanium is classified as a critical mineral by the US government due to its essential use in defence, aerospace, medical, and high-performance manufacturing. Historically reliant on imports of titanium sponge, the US has increased efforts to develop domestic production. IperionX’s focus on lower-carbon titanium production situates it within this strategic framework. Although this update concerns only a share issuance from option exercises, it reflects the company’s ongoing business centered on critical minerals development.

Implications of Dual Listing on ASX and NASDAQ for Investors

IperionX’s dual listing on the ASX and NASDAQ affects disclosure and investor access across jurisdictions. The company complies with continuous disclosure and governance requirements in both Australia and the US. The Section 708A notice filed on 15 July 2026 pertains specifically to Australian law and ASX-listed securities. Investor inquiries are handled through Australian contacts, underscoring its dual-jurisdiction governance.

Australian retail investors holding ASX-listed IPX shares can rely on the Section 708A notice to confirm the shares issued from option exercises are freely tradable and compliant with Australian regulations. US investors holding NASDAQ-listed shares are subject to corresponding US securities laws. Dual listing broadens the investor base, enhancing liquidity and capital raising potential. The immediate share price impact of this issuance was not publicly disclosed.

Risks Related to IperionX’s Business Model and Capital Structure

Investors should consider risks specific to IperionX’s business and development stage. As a company building a domestic US titanium supply chain, it faces capital-intensive development, regulatory approvals, and technological execution risks. Project timelines may extend, capital needs may increase, and market conditions for titanium and critical minerals may fluctuate, impacting economics.

From a capital structure standpoint, exercising unlisted options, as with this issuance, causes incremental dilution. If many options remain exercisable below market price, further dilution may occur. The company did not disclose outstanding options in this update. Additionally, as a dual-listed entity, IperionX incurs compliance and governance costs across two jurisdictions. Its reliance on capital markets for funding means broader market sentiment toward critical minerals significantly influences its capital raising ability.